AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca now trails Pfizer/BioNTech and likely Moderna in the race to develop a Covid-19 vaccine; as AZN stock fell as did shares of other biotech stocks amid an overall market downturn.
The post Covid Report: AstraZeneca Now Seen As Lagging In Vaccine Race appeared first on Investor's Business Daily.

Covid Report: AstraZeneca Now Seen As Lagging In Vaccine Race

AstraZeneca plc's (NYSE: AZN) prospects at being the first mover in the competition to develop a coronavirus vaccine have dimmed, according to an analyst at SVB Leerink.

AstraZeneca Has Lost The Lead In Race For Coronavirus Vaccine, Says SVB Leerink

Merck

The European Medicines Agency (EMA) has recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said on Monday.

EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers

BioNTech SE

Moderna

Pfizer

Adverse event(s?) with AstraZeneca/Oxford University Phase 3 trial need more clarity for public confidence; the adverse event(s?) came after the second dose of the vaccine.

COVID-19 Vaccine Car Crash

Johnson & Johnson

You don't have to take on a huge amount of risk to profit from these solid COVID-19 vaccine leaders.

3 Best Coronavirus Vaccine Stocks to Buy Right Now

AstraZeneca Plc said on Saturday that its COVID-19 vaccine trial in the United States is still on hold.

AstraZeneca says COVID-19 vaccine trial in U.S still on hold

Amgen

Regeneron Pharmaceuticals

Coronavirus concerns seem to be lifting as the markets churn higher, but is this a carrot-or-the-stick question?

This Week in Coronavirus News

Inovio Pharmaceuticals

Investors came back to the biotech's shares early this week. But will the optimism stick?

Are the Gains Over for This Early Leader in the Coronavirus Vaccine Race?

The latest results from a long-term study of the drug enhance the case for its use.

AstraZeneca's Lynparza Delivers Progression-Free Survival of Over 4 Years in Advanced Ovarian Cancer

There's also one other candidate that's hot on their heels.

3 Coronavirus Vaccines in Phase 3 Clinical Studies: How They Stack Up Against Each Other

Since the beginning of the pandemic, AstraZeneca (NYSE: AZN) was among the front-runners in the COVID-19 vaccine race.

Is AstraZeneca Still A Safe Bet?

CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Dogma Therapeutics ("Dogma"), a Viva Biotech Portfolio Company, has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca.

Viva Biotech's Portfolio Company Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program

You'll have a much better shot at getting a shot next year.

3 Reasons Why You Probably Won't Receive a Coronavirus Vaccine Shot by the End of 2020

CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Dogma Therapeutics ("Dogma") has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca.

Dogma Therapeutics Announces Global Acquisition of Oral PCSK9 Inhibitor Program by AstraZeneca

AstraZeneca Plc’s (NYSE: AZN) vaccine didn't likely cause the adverse events that suspended the late-stage human trials of the drug, according to Oxford University.

AstraZeneca Trial Participant Adverse Events Likely Unrelated To COVID-19 Vaccine: Oxford

“After independent review, these illnesses were either considered unlikely to be associated with the vaccine or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine.”

Illness In Paused AstraZeneca Trial Likely Wasn’t Caused By Vaccine, Oxford University Says

Astrazeneca (AZN) closed the most recent trading day at $55.13, moving -0.27% from the previous trading session.

Astrazeneca (AZN) Stock Moves -0.27%: What You Should Know

The paused clinical trial has already resumed.

Coronavirus Vaccine Trial Adverse Event Was Probably Unrelated to Treatment

AstraZeneca plc (NYSE: AZN) COVID-19 vaccine clinical trial is set to resume in India after local partner Serum Institute of India received the go-ahead from Indian regulators, Reuters reported Wednesday.

AstraZeneca Gets India Go-Ahead To Resume COVID-19 Vaccine Trials, US Nod Awaited

Gilead Sciences

Want to invest in coronavirus vaccine stocks but are worried about their risks? This portfolio has you covered.

This 3-Stock Portfolio Is a Safe Bet on a Coronavirus Vaccine

AstraZeneca's AZN, +2.33% AZN, -0.02% Phase 3 trial for its COVID-19 vaccine candidate is still on hold in the U.S.

Hahn: AstraZeneca's COVID-19 vaccine trial is still on hold in the U.S.

iShares MSCI USA Quality Factor ETF

Invesco S&P 500 Quality ETF

Invesco S&P 500 Low Volatility ETF

iShares Edge MSCI Min Vol USA ETF

.S. markets may have bounced back at the news of AstraZeneca???s (AZN) resumption of its phase 3 trial, but gains have been limited as the fear factor remains in investors?

Why Is This the Right Time to Invest in Low-Volatility ETFs?

This comes on the heels of a resumption in the company's U.K. trial for AZD1222.

AstraZeneca Resumes COVID-19 Vaccine Candidate Trial in South Africa

Biogen

Momenta Pharmaceuticals

Neoleukin Therapeutics Inc

Perrigo

Relmada Therapeutics Inc

Sanofi

Supernus Pharmaceuticals

Takeda Pharmaceutical

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Pharmaceutical Stocks for Q4 2020

Veeva Systems

BARCELONA, Spain--(BUSINESS WIRE)--AstraZeneca selects Veeva Vault QMS and Veeva Vault QualityDocs to increase visibility, efficiency, and speed across quality processes.

AstraZeneca Selects Veeva Vault Quality Suite to Modernize Global Quality Management

News for AstraZeneca Stock (AZN)